Page 19 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

Syringe storage 39
If the syringe containing fixed-dose SC combination of trastuzumab and
pertuzumab is not used immediately, it can be stored in the refrigerator for up to

24 hours (2°C to 8°C, 36°F to 46°F) and at room temperature for up to 4 hours
(20°C to 25°C, 68°F to 77°F). Avoid unnecessary storage.

 If the dose is not to be administered immediately, and the solution of fixed-dose
SC combination of trastuzumab and pertuzumab has been withdrawn from

the vial into the syringe, replace the transfer needle with a syringe closing cap.
 Do not attach a hypodermic needle until time of administration to avoid needle
clogging.

 Label the syringe with the peel-off sticker.

7.4. Treatment regimens for eBC and mBC, based on pertuzumab studies and

FeDeriCa

eBC treatment regimen 35,39

Eligible patients with HER2+ eBC should receive fixed-dose SC combination of
trastuzumab and pertuzumab every 3 weeks to complete 1 year of treatment (up

to 18 cycles) or until disease recurrence or unmanageable toxicity, whichever
occurs first, as part of a complete treatment regimen including anthracycline-
and/or taxane-based chemotherapy.

Neoadjuvant chemotherapy regimens

Neoadjuvant Setting Adjuvant Setting

4 cycles of fixed-dose SC combination of 3 postoperative cycles of FEC† and continue fixed-
trastuzumab and pertuzumab + docetaxel* dose SC combination of trastuzumab and
(based on pertuzumab studies) pertuzumab to complete 1 year (up to 18 cycles) of
treatment per full Prescribing Information

3 or 4 cycles of FEC, followed by 3 or 4 cycles of
†
fixed-dose SC combination of trastuzumab and
pertuzumab + docetaxel (based on pertuzumab S
*
studies) U
R
6 cycles of fixed-dose SC combination of Continue fixed-dose SC combination of
trastuzumab and pertuzumab + docetaxel + G trastuzumab and pertuzumab to complete 1 year
*
carboplatin (based on pertuzumab studies) E (up to 18 cycles) of treatment per full Prescribing
‡
R Information
§
4 cycles of ddAC, followed by 4 cycles of fixed-dose Y
SC combination of trastuzumab and pertuzumab +
paclitaxel or docetaxel (based on a pertuzumab
*
||
study and FeDeriCa)
4 cycles of AC, followed by 4 cycles of fixed-dose SC
¶
combination of trastuzumab and pertuzumab +
docetaxel (based on FeDeriCa)
*
M-AE-00000086 19